X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ELDER PHARMA VENUS REMEDIES/
ELDER PHARMA
 
P/E (TTM) x -4.7 -0.2 - View Chart
P/BV x 0.1 0.1 138.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ELDER PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
ELDER PHARMA
Jun-14
VENUS REMEDIES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs143380 37.6%   
Low Rs65188 34.6%   
Sales per share (Unadj.) Rs324.2491.2 66.0%  
Earnings per share (Unadj.) Rs6.4-3.2 -201.5%  
Cash flow per share (Unadj.) Rs40.614.4 281.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.0376.5 97.2%  
Shares outstanding (eoy) m12.3420.54 60.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 55.4%   
Avg P/E ratio x16.2-89.3 -18.2%  
P/CF ratio (eoy) x2.619.7 13.0%  
Price / Book Value ratio x0.30.8 37.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,2825,833 22.0%   
No. of employees `0000.9NA-   
Total wages/salary Rs m2512,179 11.5%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,00010,089 39.7%  
Other income Rs m23257 8.8%   
Total revenues Rs m4,02310,346 38.9%   
Gross profit Rs m785-792 -99.1%  
Depreciation Rs m422361 116.7%   
Interest Rs m3442,756 12.5%   
Profit before tax Rs m42-3,653 -1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m-37125 -29.6%   
Profit after tax Rs m79-65 -121.0%  
Gross profit margin %19.6-7.8 -249.9%  
Effective tax rate %-87.9-3.4 2,565.2%   
Net profit margin %2.0-0.6 -305.3%  
BALANCE SHEET DATA
Current assets Rs m2,6069,240 28.2%   
Current liabilities Rs m1,9809,998 19.8%   
Net working cap to sales %15.6-7.5 -208.3%  
Current ratio x1.30.9 142.4%  
Inventory Days Days12846 277.0%  
Debtors Days Days4360 72.0%  
Net fixed assets Rs m5,35310,124 52.9%   
Share capital Rs m123206 60.0%   
"Free" reserves Rs m4,3935,582 78.7%   
Net worth Rs m4,5167,734 58.4%   
Long term debt Rs m1,6184,889 33.1%   
Total assets Rs m8,29122,882 36.2%  
Interest coverage x1.1-0.3 -345.1%   
Debt to equity ratio x0.40.6 56.7%  
Sales to assets ratio x0.50.4 109.4%   
Return on assets %5.111.8 43.4%  
Return on equity %1.8-0.8 -207.3%  
Return on capital %6.322.3 28.2%  
Exports to sales %03.0 0.0%   
Imports to sales %18.40.4 4,308.6%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs m73643 1,708.4%   
Fx inflow Rs m0307 0.0%   
Fx outflow Rs m736125 587.6%   
Net fx Rs m-736181 -406.1%   
CASH FLOW
From Operations Rs m99711,754 8.5%  
From Investments Rs m-461-561 82.3%  
From Financial Activity Rs m-571-6,762 8.4%  
Net Cashflow Rs m-354,432 -0.8%  

Share Holding

Indian Promoters % 32.9 39.6 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 16.8 3.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.1 183.9%  
Shareholders   20,121 16,479 122.1%  
Pledged promoter(s) holding % 36.4 77.6 46.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES  GLENMARK PHARMA  SUN PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS